491 related articles for article (PubMed ID: 26405193)
1. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
Moeini A; Sia D; Bardeesy N; Mazzaferro V; Llovet JM
Clin Cancer Res; 2016 Jan; 22(2):291-300. PubMed ID: 26405193
[TBL] [Abstract][Full Text] [Related]
2. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
3. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
4. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
[TBL] [Abstract][Full Text] [Related]
5. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
[TBL] [Abstract][Full Text] [Related]
6. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
8. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
10. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK; Bridgewater J; Gores GJ; Zhu AX
J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
13. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.
Choi JH; Thung SN
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672619
[TBL] [Abstract][Full Text] [Related]
15. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
16. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.
Sia D; Tovar V; Moeini A; Llovet JM
Oncogene; 2013 Oct; 32(41):4861-70. PubMed ID: 23318457
[TBL] [Abstract][Full Text] [Related]
18. Molecular Profile and Prognostic Value of
Rizzo A; Carloni R; Ricci AD; Di Federico A; Guven DC; Yalcin S; Brandi G
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 36013199
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study.
Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679
[TBL] [Abstract][Full Text] [Related]
20. Molecular classification of cholangiocarcinoma.
Louis C; Papoutsoglou P; Coulouarn C
Curr Opin Gastroenterol; 2020 Mar; 36(2):57-62. PubMed ID: 31895230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]